NCT06239727 2026-03-06
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
10 trialsNCT07303283 2026-03-05
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
Guangxi Medical University
Phase 2 Not yet recruiting
NCT05126719 2026-02-06
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Shanghai Miracogen Inc.
Phase 2 Active not recruiting
NCT06976190 2026-01-20
Magic-C002
Shanghai Miracogen Inc.
Phase 3 Recruiting
NCT07331428 2026-01-09
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07248670 2025-11-25
Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC
Chongqing University Cancer Hospital
Phase 3 Active not recruiting
NCT06118333 2025-09-30
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT06987123 2025-05-23
TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT04517214 2025-04-02
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Fudan University
Phase 2 Active not recruiting
NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting